CCS Clears Proposed Acquisition of assets by Zuellig Pharma Holdings Pte. Limited
5 May 2026
1. The Competition and Consumer Commission of Singapore (“CCS”) has cleared the proposed acquisition of certain assets by Zuellig Pharma Holdings Pte. Limited and its relevant affiliates (the “Applicant”) from Eli Lilly and Company and its relevant affiliates (“Lilly”) (collectively, the “Parties”) (the “Proposed Transaction”).
2. CCS has concluded that the Proposed Transaction will not result in a substantial lessening of competition in relation to the markets for the supply and distribution of erectile dysfunction (“ED”) medications in Singapore.
3. Following CCS’s assessment of the Applicant’s submissions and third-party feedback, CCS concluded that the relevant markets are likely to remain competitive, given that Cialis[1] is not a must-have product for distributors seeking to sell their other products, and that the Applicant would not be able to preferentially promote Cialis over other ED medications it distributes.
4. Refer to CCS’s public register for more information.
[1]Cialis is a prescription medication used to treat ED.
